Research & Development

Overview

The Julphar Research Centre dedicated to the Formulation of Research and Product Development (PDL) develops all types of dosage forms – such as solid orals, liquid orals, parenteral including lyophilized injections, powder for injections, ointments, creams, suppositories, effervescent tablets, sustained release and delayed release capsules and tablets.

The main focus of the PDL Centre is to develop:

  • Bio-equivalent generic drug products;
  • First-to-file products in the region which are still under patent protection;
  • Novel drug delivery systems and dosage forms;
  • Regulatory submissions in CTD format.

The analytical support function provides new analytical method development, method validation, conduction of stability studies as per the International Conference on Harmonisation (ICH) guidelines.

The PDL team supports the company to stay competitive in the pharmaceutical industry and is responsible for creating innovative and cost-efficient products, methods and processes to keep Julphar a step ahead of the competition.

More than 800 products in different dosage forms have been developed and registered in more than 40 countries including delayed release, sustained release products, hydrogels, emulgels, effervescent tablets, and fixed dose combination products – covering all therapeutic categories.